Skp2 targeting suppresses tumorigenesis by Arf-p53-independent cellular senescence

This corrects the article DOI: 10.1038/nature08815

[1]  M. Pagano,et al.  Role of the F-box protein Skp2 in lymphomagenesis , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[2]  Xin Lin,et al.  The E3 Ligase TRAF6 Regulates Akt Ubiquitination and Activation , 2009, Science.

[3]  M. Barbacid,et al.  Tumour biology: Senescence in premalignant tumours , 2005, Nature.

[4]  P. Pandolfi,et al.  Skp2 targeting suppresses tumorigenesis by Arf-p53-independent cellular senescence , 2010, Nature.

[5]  P. Pandolfi,et al.  Cytoplasmic PML function in TGF-β signalling , 2004, Nature.

[6]  Pier Paolo Pandolfi,et al.  Tenets of PTEN Tumor Suppression , 2008, Cell.

[7]  Patrick J. Paddison,et al.  An epi-allelic series of p53 hypomorphs created by stable RNAi produces distinct tumor phenotypes in vivo , 2003, Nature Genetics.

[8]  S. Gruber,et al.  Anti-oncogenic role of the endoplasmic reticulum differentially activated by mutations in the MAPK pathway , 2006, Nature Cell Biology.

[9]  Pier Paolo Pandolfi,et al.  The Multiple Roles of PTEN in Tumor Suppression , 2000, Cell.

[10]  Richard A. Ashmun,et al.  Tumor Suppression at the Mouse INK4a Locus Mediated by the Alternative Reading Frame Product p19 ARF , 1997, Cell.

[11]  S. Lowe,et al.  Premature senescence involving p53 and p16 is activated in response to constitutive MEK/MAPK mitogenic signaling. , 1998, Genes & development.

[12]  J. Gervais,et al.  Human CUL-1 associates with the SKP1/SKP2 complex and regulates p21(CIP1/WAF1) and cyclin D proteins. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[13]  John Calvin Reed,et al.  Cell death and endoplasmic reticulum stress: disease relevance and therapeutic opportunities , 2008, Nature Reviews Drug Discovery.

[14]  D. H. Randle,et al.  Tumor spectrum in ARF-deficient mice. , 1999, Cancer research.

[15]  Amanda Doucette,et al.  An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer , 2009, Nature.

[16]  M. Loda,et al.  Differential p53-Independent Outcomes of p19Arf Loss in Oncogenesis , 2009, Science Signaling.

[17]  E W Martz,et al.  Crime and punishment? , 1992, Delaware medical journal.

[18]  M. Kitagawa,et al.  Targeted disruption of Skp2 results in accumulation of cyclin E and p27Kip1, polyploidy and centrosome overduplication , 2000, The EMBO journal.

[19]  Y. Kuo,et al.  Activation of the anaphase promoting complex by HTLV‐1 tax leads to senescence , 2006, The EMBO journal.

[20]  N. Sharpless,et al.  The Regulation of INK4/ARF in Cancer and Aging , 2006, Cell.

[21]  Dimitris Kletsas,et al.  Oncogene-induced senescence is part of the tumorigenesis barrier imposed by DNA damage checkpoints , 2006, Nature.

[22]  P. Yaswen,et al.  Oncogene-Induced Senescence Pathways Weave an Intricate Tapestry , 2007, Cell.

[23]  R. DePinho,et al.  Cancer: Crime and punishment , 2005, Nature.

[24]  J. Mestan,et al.  Skp2 is oncogenic and overexpressed in human cancers , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[25]  T. Jacks,et al.  Restoration of p53 function leads to tumour regression in vivo , 2007, Nature.

[26]  S. Lowe,et al.  Oncogenic ras Provokes Premature Cell Senescence Associated with Accumulation of p53 and p16INK4a , 1997, Cell.

[27]  Michele Pagano,et al.  Deregulated degradation of the cdk inhibitor p27 and malignant transformation. , 2003, Seminars in cancer biology.

[28]  K. Nakayama,et al.  Regulation of the cell cycle by SCF-type ubiquitin ligases. , 2005, Seminars in cell & developmental biology.

[29]  P. Pandolfi,et al.  Impaired Fas response and autoimmunity in Pten+/- mice. , 1999, Science.

[30]  Aaron Bensimon,et al.  Oncogene-induced senescence is a DNA damage response triggered by DNA hyper-replication , 2006, Nature.

[31]  Frédérick A. Mallette,et al.  The DNA damage signaling pathway is a critical mediator of oncogene-induced senescence. , 2007, Genes & development.

[32]  P. Pandolfi,et al.  Phosphorylation-dependent regulation of cytosolic localization and oncogenic function of Skp2 by Akt/PKB , 2009, Nature Cell Biology.

[33]  H. Stein,et al.  Oncogene-induced senescence as an initial barrier in lymphoma development , 2005, Nature.

[34]  L. Cantley,et al.  New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[35]  Hong Sun,et al.  Expression of the F-box protein SKP2 induces hyperplasia, dysplasia, and low-grade carcinoma in the mouse prostate. , 2003, Cancer research.

[36]  J. Shay,et al.  BRAFE600-associated senescence-like cell cycle arrest of human naevi , 2005, Nature.

[37]  M. Pagano,et al.  S-phase kinase-associated protein 2 expression in non-Hodgkin's lymphoma inversely correlates with p27 expression and defines cells in S phase. , 2002, The American journal of pathology.

[38]  Jason A. Koutcher,et al.  Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis , 2005, Nature.

[39]  E. Wagner,et al.  Down‐regulation of wild‐type p53 activity interferes with apoptosis of IL‐3‐dependent hematopoietic cells following IL‐3 withdrawal. , 1994, The EMBO journal.

[40]  Carlos Cordon-Cardo,et al.  Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas , 2007, Nature.

[41]  Carlos Cordon-Cardo,et al.  Pten is essential for embryonic development and tumour suppression , 1998, Nature Genetics.

[42]  S. Signoretti,et al.  VHL loss actuates a HIF-independent senescence programme mediated by Rb and p400 , 2008, Nature Cell Biology.

[43]  K. Nakayama,et al.  Absence of Skp2 Expression Attenuates Bcr-abl-induced , 2008 .